https://www.businesswire.com/news/home/20220615005625/en/
Aileron Therapeutics Provides Business Update And Outlines 2022 Strategic Priorities To Deliver Key Milestones
Plans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim results expected in 4Q22
Planned readouts for ongoing randomized, double-blind, placebo-controlled non-small cell